On Friday, KalVista Pharmaceuticals Inc (NASDAQ: KALV) was 4.09% up from the session before settling in for the closing price of $13.80. A 52-week range for KALV has been $7.30 – $15.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -3.28%. With a float of $38.50 million, this company’s outstanding shares have now reached $49.49 million.
In an organization with 150 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 63.27%, operating margin of -15043.2%, and the pretax margin is -14230.76%.
KalVista Pharmaceuticals Inc (KALV) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward KalVista Pharmaceuticals Inc stocks. The insider ownership of KalVista Pharmaceuticals Inc is 22.56%, while institutional ownership is 88.37%. The most recent insider transaction that took place on May 23 ’25, was worth 24,272. In this transaction CHIEF MEDICAL OFFICER of this company sold 2,146 shares at a rate of $11.31, taking the stock ownership to the 113,026 shares. Before that another transaction happened on May 23 ’25, when Company’s CHIEF DEVELOPMENT OFFICER sold 1,926 for $11.31, making the entire transaction worth $21,782. This insider now owns 98,189 shares in total.
KalVista Pharmaceuticals Inc (KALV) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.36% during the next five years compared to -20.06% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
You can see what KalVista Pharmaceuticals Inc (KALV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -2.98 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Let’s dig in a bit further. During the last 5-days, its volume was 0.68 million. That was better than the volume of 0.52 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 93.91%. Additionally, its Average True Range was 0.67.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 99.50%, which indicates a significant increase from 98.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.13% in the past 14 days, which was lower than the 53.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.12, while its 200-day Moving Average is $10.91. However, in the short run, KalVista Pharmaceuticals Inc’s stock first resistance to watch stands at $14.54. Second resistance stands at $14.71. The third major resistance level sits at $15.02. If the price goes on to break the first support level at $14.06, it is likely to go to the next support level at $13.75. The third support level lies at $13.58 if the price breaches the second support level.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
There are 49,716K outstanding shares of the company, which has a market capitalization of 714.17 million. As of now, sales total 0 K while income totals -126,640 K. Its latest quarter income was 0 K while its last quarter net income were -48,510 K.
